Alicia Secor (Atalanta)
Genentech and Biogen roll the dice on an upstart biotech with a new siRNA approach — going deep into the brain for targets in neurodegeneration
Atalanta isn’t your average stealth biotech making a debut. They have some history and deals to sketch out in rough outlines.
The founding execs date …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
